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1. Introduction   
Invasive fungal infections (IFI) are serious diagnostics-therapeutic problem in recipients of 
vascularised organs. The nature of the IFI is determined by the type of the transplanted 
organ. Invasive candidiasis mostly occurs in liver recipients and invasive aspergilosis – in 
lung recipients. The greatest risk of IFI is in recipients of simultaneous lung and heart and 
liver transplants. Morbidity for IFI in the first year after transplantation is estimated to be in 
recipients of heart and lungs 8.6%, liver 4.7%, pancreas and kidneys 4% and heart 3.4%.  
Incidents of IFI among kidney recipients is estimated by differed sources to lay between 0.01 
– 1.5%. Although, IFI occur rarely in kidney recipients in comparison to recipients of other 
organs, invasive fungal infections carries a high risk of graft loss and high mortality in this 
population of patients. Among recipients which have developed an IFI the risk of graft loss 
was determined in approx. 50% of patients, and mortality in this group was approx. 15%. 
Yearly survival of patients after an episode of invasive aspergilosis is 59%, for mycosis 
caused by mould fungi from species other then Aspergillus sp. 61%, invasive candidosis 66%, 
cryptococcosis 73%. There is definitely a greater risk for recipients of kidneys collected from 
cadavers, compared to living donors related to the recipient, respectively 16.5% and 7.3%. 
Additionally in cases of a deceased donor there is a high transfer risk for yeast-like fungi 
colonising in the urinary tract of a terminal state patient, in result of the breakdown of the 
defensive mechanism and contamination of preservative fluids, to the uninfected recipient.  
Mortality is determined by the virulence of the microorganism, localisation of the infection, 
weakened inflammatory response of the macroorganism, frequent co-occurring of renal 
insufficiency and diabetes and other predisposing factors. Unspecific clinical symptoms, fast 
progression of the disease and, what appears to be particularly important, lack of a precisely 
set algorithms of diagnostic procedure, contribute to the fact that IFI in kidney recipients are 
a diagnostics challenge and has a questionable therapeutic result.  
1.1 Factors for fungal infections 
Factors for fungoid infections: 
- impairment of cellular resistance 
- congenital genetic defects in phagocythosis, complement system 
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- use of immunosuppressants, cytostatics, broad spectrum antibiotics, corticosteroids  
- interruption of tissue continuity (insertion of a needle into a vessel, diagnostic 
puncture) 
- inflammatory disorders and functional in the gastrointestinal tract (favourable factors 
for translocation of fungi from  the intestinal lumen)   
- catheterization of the urinary bladder 
- parenteral feeding 
- dialysis therapy   
- surgical procedures, particularly in the abdominal cavity 
- tracheotomy, intubation, endoscopy  
- blood transfusion 
- tuberculosis 
- metabolic disorders  
- endocrinological disorders 
- pregnancy 
- extreme age groups 
- nutritional factors (intake of food containing moulds – strains used in food production 
or contaminants). 
Patients with final renal insufficiency qualified for the transplant procedure, despite the 
main illness, often have also at least a few of the risk factors described above, are part of the 
population particularly predisposed to developed an IFI. There is a very high risk of IFI 
occurrence in recipients which had consecutive kidney transplant procedures, recipients of a 
simultaneous pancreas and kidney transplant and highly immunised recipients, requiring 
induction of the immunosuppression with anti-thymocyte globulin.  
1.2 The remaining infection risk factors 
The remaining infection risk factors differ depending on the period after the kidney 
transplant. 
1.2.1 Early period 
Early period – 1 month after kidney transplant. Mostly infections are caused by yeast-like 
fungi: Candida sp., Trichosporon sp., Saccharomyces sp. Risk factors in this period are related to 
the used surgical technique, transfer of the fungal infection form the infected organ or 
preservative fluid or fungal colonization form a period before the transplant. Infection with 
mould fungi of the Aspergillus genus are rare and are related to the prolonged operation 
time or organ transport. 
1.2.2 Interim period 
Interim period – from 2 to 6 months. Among etiological factors, yeast-like fungi responsible 
for infections in the early period are predominant, as well as mixed fungoid-bacterial 
infections. The basic risk factor in this time is a weakened immunological response due to: 
- infections and/or reactivation of immunomodulation viruses: CMV, HIV, EBV, HBV, 
HCV and other 
- site effects of transplanted kidney rejection therapy, with high doses of corticosteroids 
or other cytotoxic lymphocyte  inhibitors. 
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1.2.3 Late period 
Late period – over 6 months. Relatively often occurring infection in this period is the 
cryptococcosis, often in scattered form. Other etiological factors for IFI are yeast-like fungi, 
mould fungi of the Aspergillus genus and others. In this period the level of basic 
immunosuppression is remained on a low level, which means that in cases without 
complications the state of the recipients immunological system is close to the state of the 
general population’s. IFI episodes are sporadic and caused by an individual course of the 
post-transplantation period or individual predispositions: 
- complications in previous periods in graft function – treatment of acute rejection 
episodes 
- exceeding of drug level limits of the basic immunosuppression protocol in systemic 
fluids  
- reactivation of infections with immunomodulation viruses  
- environmental factors. 
1.3 Difficulties due to lack of an effective strategy for mycological diagnostics 
Difficulties due to a lack of an effective strategy for mycological diagnostics and often sparse 
clinical symptoms are the reason that important data for diagnosis of invasive mycosis on 
kidney recipients are undervalued. Statistics on mortality due to disseminated mycosis do 
not contain, also for reasons outlined here, all cases. Lack of specific symptoms indicating an 
early period of an IFI, or transition of colonization into an active infection, lack of criteria 
allowing differentiation of infections and colonisations and in result lack of precisely 
described evidence for implementation of preventive – therapeutic treatment. Also 
important is to decide – does every positive mycological result, obtained by classic 
diagnostic methods, mean an infection and the necessity to implement antimycotic therapy, 
and does every colonising strain cause systemic infections, also which genotype and 
phenotype can benefit this process. 
Additionally the treatment of a developed invasive fungal infection carries a high risk for 
patients due to frequent interactions between antimycotics and immunosuppressants. 
Taking this into account, it appears to be of outmost importance to develop a diagnostics 
algorithm minimising the risk of IFI in kidney recipients, based on an active surveillance of 
particularly predisposed recipients. 
2. Invasive systemic mycosis: aspergilosis  
Invasive aspergilosis (IA) is an acute infection with a mortality rate of almost 70%. Mostly it 
occurs in recipient of allogeneic bone marrow from an unrelated recipient – 10.3%.  Among 
organ recipients lung recipients (Lung Transplant) are at highest risk, with morbidity at 
8.4%. Among heart recipients (Heart Transplant) morbidity for IA is estimated to be 6.2%, 
liver (Liver Transplant) –1.7%, pancreas (Pancreas Transplant) –1.3%. Morbidity in kidney 
recipients (Kidney Transplant) applies for 0.7% of patient population. 
An etiological factor in more then 90% of cases is Aspergillus fumigatus. Another species of 
clinical importance are: Aspergillus niger, Aspergillus flavus and Aspergillus terreus. Different 
species participation is to be observed in external and middle ear aspergilosis, in most cases 
Aspergillus flavus and Aspergillus niger are responsible. 
Aspergillus spores are now generally present in the environment. Etiology of Aspergillus 
infections are usually results of Aspergillus inhalation. The invasive form is the most severe 
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form of infection. In the initial stage, spores infect the lungs (pulmonary aspergilosis), next 
they get into cardiovascular vessels and to other locations eg.: sinuses (nasal sinus 
aspergilosis), eyes, skin, kidneys, bones, central nervous system (CNS aspergilosis). 
The most common clinical manifestation is lung aspergilosis – 75% of all IA cases, 
rhinosinusitis (infection of the nasal mucosa and nasal sinuses) -  5 – 10%, disseminated 
multiorgan – 25%, IA with an affected central nervous system makes out 10 – 40% of all 
cases. 
IA Diagnostic: an early diagnostic is critical for an effective therapy, also to avoid the 
unnecessary administration of a costly and toxic antimycotic therapy. 
Traditional methods: as a „golden standard” in the diagnostic of invasive aspergilosis until 
now, remains the cultivation of a strain from the sample clinical material and identification 
fungi fimbriae by histopathology.  
Appropriate test materials are bronchalalveolar washings in case of pulmonary aspergilosis 
and sinus washings in rhinosinusitis with Aspergillus etiology. The value of a mycological 
rest of sputum is restricted by its low sensitivity and specificity, difficulties in obtaining 
enough material (lack of a productive cough in the treated patient) or a frequent lack of 
morphologic elements of fungi and spore.  In cases when it is not possible to sample 
material with invasive methods, morning sputum should be sampled a few times, on 
consecutive days, with securing of the material from contamination. 
A difficult to diagnose form of aspergilosis is the disseminated multiorgan form. In this case 
the probability to cultivate an etiological factor from blood is infinitesimal compared to 
disseminated infections caused by other microorganisms (yeast-like fungi and bacteria). In 
case of invasive aspergilosis with the seizure of central nervous system, cerebrospinal fluid 
and serum become materials of questionable significance, the only valuable diagnostically 
material in this case is biopsy material sampled from the lesion. Diagnostic in this case 
should be based on precise analysis of all available tests: exact evaluation of the interview 
data, subject test results, biochemical tests results, assessment of the inflammation 
exponents, and results of imaging tests. As supportive tests can be used: detection of 
galactomannan antigen and genetic fungi material in cerebrospinal fluid and in serum.  
Validity of the mycological test depends on the correct performance of every stage. Material 
sampling should be assisted by a microbiology specialist or a specially trained physician. It 
is necessary to take an appropriate number of samples and to sample material on the right 
microbiological medium for cultivation and direct microscopic preparation. Microscopic 
testing of clinical material and the correct evaluation are an immensely important stage of 
the diagnostic, which should be taken into account at sampling: sample material with a 
sterile smear dampened in a sterile 0.9% NaCl solution, transport medium should not be 
used for this purposes.  
Histopathology diagnostic value is particularly important due to a relatively short time of 
waiting for results, high sensitivity and possibility to obtain positive results in an ongoing 
antimycotic therapy and is based on detection of fungal fimbriae. This method is restricted 
by lack of microorganism identification possibility and antimycotics sensitivity assessment, 
which can be preformed only on the basis of mycological cultivation. 
Microscopic tests or cultivation are a limited possibility to retain testing material, only 
invasive methods and is connected to long results awaiting period.  
Biopsy can be dangerous in case of weakened patients. 
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Fig. 1. Aspergillus fumigatus: 1 Microscopic slide (x400) Microscopic tests of expectoration or 
BAL, 2 Colonies on Sabouraud Agar. 3 Mucor spp. Microscopic sidle (x400). 
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Fig. 2. 1 Invasive form of Candida albicans in blood (x1000), 2 Trichosporon asahii, microscopic 
slide (x400), 3 Cryptococcus neoformans. India Ink preparation (x400) 
3. Infection with mould fungi other than Aspergillus supp. (non-Aspergillus 
mould infections): zygomycosis 
Zygomycosis – is an invasive infection frequently with Mucor spp., Rhizopus spp., Rhizomucor 
spp., Absidia spp. fungi of the Zygomycota division. It has been noted in the past years that the 
number of zygomycosis in the general number of infections with mould fungi in a general 
population of recipients from 4% to 25% in the period between 2001 and 2003 has increased.  
Mostly the infection will have a sinusitis form with a tendency to quickly spread to the 
central nervous system – rhinocerebral form. Additionally the following forms can be 
observed: pulmonary, cutaneous and subcutaneous tissue infection, renal, gastrointestinal 
tract and disseminated form, often diagnosed post-mortem. 
Most important risk factors of this type of infection are: persisting acidosis caused by a 
badly monitored diabetes or renal insufficiency and immunosuppressive therapy, 
particularly in connection with chronic nasal sinus infection. In the organ recipients 
population as the most important risk factor was perceived a previous exposition to 
voriconazole therapy of a previous infection with yeast-like fungi or Aspergillus spp. Often 
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those are „infections with breaking-point” with strains belonging to species,  which do not 
fall in the spectrum of this drug.  
Cases of zygomycosis in kidney recipients population in industrialised countries are rarely 
documented, but in developing countries: India, Pakistan, and Iran – they are quite 
common. Also the trend of „transplant tourism” observed in the last years – travelling to 
„third world” countries for transplants due to economic reasons and greater availability of 
organs, while trivialising a great risk of complications.  
Rejections of transplanted organs and infection complications are serious problems, which 
European doctors providing post-transplant care for patient in this group may have to face. 
Aspergilosis with mucormycosis are most common infection complications in patients who 
have practised this kind of „tourism”.  
The death rate in this group is estimated at 59%, and further 82% suffer from graft loss, or 
from a disseminated form of infection with an infection of the central nervous system. The 
diagnostic procedure for zygomycosis is norm for all mould fungi and has been described in 
the chapter in aspergilosis diagnostics. 
4. Invasive yest-like fungi  
4.1 Invasive candidiasis (IC) 
The most important exponent of the invasive candidosis is candidemia – fourth in frequency 
etiological factor of in hospital blood infection (BSI): 6-10% of the total positive blood culture 
in hospitalised patients. In patients after vascularised organ transplantation, IC makes out 
53% of all IFI.  
Infections with yeast-like fungi occur in 5% of kidney recipients with a death rate between 
30 - 70%. Most common forms of candidosis among kidney recipients are mucosa-cutaneous 
and oesophagus candidosis. Heavy complications endangering the survival of the 
transplant are urinary tract infections: cystitis, pielonephritis and ureteral obstruction by 
Candida elements.  
In an early period it is often conditioned by a colonisation of yeast-like fungi in the 
insufficient kidney in a period before the transplant and presence of urinary catheters in a 
post operational period, the presence of which connected with a high level of 
immunosuppression makes the spreading of the colonisation to the membrane and an 
invasive infection easier. Also a very important mechanism of developing a urinary tract 
infection is the pathogen translocation form the intestinal lumen. In this case it is an 
endeogenic infection, but with the wrong medical care and hospital hygiene it can cause 
spreading of the yeast-like fungi from the exogenous source.  
Urinary tract infections with occurrence of additional factors can lead to candidemia, 
spreading of the infection and vascular complications on the transplanted kidney. Invasion 
of yeast-like fungi to the vascular endothelium  can lead to arteritis or aneurysms.  
Complications can lead to graft loss or patients death. Other dangerous fungal infections are 
suprainfections of fluid vessels forming around the transplanted kidney, peritoneum 
infection and catheter fungemia.    
The most important factor in invasive candidosis remains the species Candida albicans but 
there is an observed growing participation of non – albicans Candida spp. to which belong: C. 
glabrata, C. tropicalis, C. parapsilosis. This species are characterised by being more drug 
resistant compared to C. albicans. The species C. glabrata shows a natural lower sensitivity to 
Fluconazole, and C. parapsilosis – to echinocandin.  
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One of the reasons for a larger participation of species of non – albicans Candida spp. 
possibly can be related to the wide use of prophylactic antifungal drugs. C. parapsilosis is 
characterised by a larger adhesion ability and the ability to produce a biofilm on the surface 
of biopolymers, including vascular catheters, which often is related to spreading of 
microorganisms colonised in the catheter into the system. 
Widely used fluconazole prophylactic can also be one of the reasons for a larger 
participation of the Trichosporon species as a etiological factor for IFI. Trichosporon spp. is not 
the most important etiological factor for fungal infections in immunocompetent patients.  
It can be a reason for an invasive mycoses in patients after vascularised organ transplant, 
with a high death rate. Trichosporon spp. is a yeast-like fungi generally occurring in nature.  
Trichosporon asahii mostly is connected with surface infections such as white piedra, skin and 
nails mycoses in immunocompetent patients. Among the species of Trichosporon T. asahii  is 
the main reason for deep invasive infections in patients treated with immunosuppressants.   
The most important factor predisposing for this kind of infections are renal insufficiency, 
phagocytolic disability and neutropenia. Mortality in result of infections with Trichosporon 
fungi is estimated to be 80-100%, which can be related to the late diagnosis of the etiologic 
factor, wrong treatment and lack of correlation between the efficacy of treatment and 
sensitivity of the strain in vitro.  
Additionally one of the characteristics of this species, which makes the prognosis of the 
course of the infection pessimistic is the variable sensitivity to amphotericin B. It can enable 
the strain Trichosporon asahii to produce biofilm. 
4.2 Diagnostics of yeast-like infections  
Clinical symptoms of IFI in kidney recipients are sparse and lack specificity, which makes a 
quick diagnosis difficult and effects efficacy of treatment and the predictions.  
Classic mycological diagnostic methods: microscopic tests, culture of clinical material, 
identification of biochemical strain of pathogen, testing of drug resistance remain standard 
diagnostics. Those methods are without doubt very important in most cases and allow to 
implement a target treatment including a minimal inhibitory concentration of specific 
antifungal drugs to the etiological factor IFI.  
It has to be stressed that sensitivity and specificity of the classic mycological diagnostic 
method are insufficient to be used as a single element for the confirmation of IFI diagnostic.  
An additional problem is the often occurring mucocutaneous colonization, which causes 
result interpretation difficulties – not every positive result for the mycological culture allows 
to implement an antifungal therapy and not every negative result of the culture excludes an 
invasive infection.   
Sparse symptoms of a systemic infection and the difficulties in a quick mycological 
diagnosis are reasons for delays in implementing of an appropriate antifungal therapy, 
which can result in the loss of the graft and even the death of the patient.  
The problem to identify the participation of the infection appears interesting, also in those 
caused by fungi in organ rejection. 
The „golden standard” in diagnostic of invasive candidosis in patients in high risk groups 
remains blood cultivation, which has serious restrictions. The most important are: 
- low sensitivity: approx. 50% of results in patients with a confirmed or possible IC can be 
a false negative 
- long result waiting time: in most case the waiting time is longer then 2 up to 3 days, in 
patients receiving antifungal drugs even 14 days.  
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Developed are also other criteria allowing a rather quick identification, if the active 
monitoring strategy of the patients state has been adjusted to the mycological diagnostic. 
One of this criteria is determining if the yeast-like fungi in culture of clinical material is 
received from one or more parts of the body.  
Diagnostic of the invasive candidosis leading to the implementation of the appropriate 
antifungal treatment consists of clinical, radiological and microbiological tests results.  
4.3 Cryptococcosis  
To the Cryptococcus belong 37 species. The most important pathogenic species for humans is 
Cryptococcus neoformans widely spread in nature globally.  
Infection vectors are birds, mostly pigeons, infection sources are also soil particles 
containing bird faeces contaminated with the fungi, and the most common infection 
mechanism is inhalation. 
A specific characteristic of the yeast-like fungi from the Cryptococcus species, used in 
diagnostic routine is a lack of a polysaccharide capsule with an antiphagocytic function. 
Cryptococcosis is an opportunistic infection in patients with immunological defects, it is 
known as an indicative illness for AIDS. The primary infection localisation are the lower 
airway, from which it quickly spreads to the lungs and the CNS.  
The most dangerous clinical form of cryptococcosis is menigoencephalitis, other clinical 
forms: chronic or acute pulmonary form or disseminated in relation to the CNS, skin and 
other tissue and organs. After the pulmonary stage and spreading to the CNS, in the blood 
serum and PMR rapidly appear dissolving capsule antigens, possible to detect with enzyme 
immunoassay methods.  
The cryptococcosis diagnostic is based on: 
- microscopic determination of yeast cells with a polysaccharide capsule in cerebrospinal 
fluid 
- microbiological cultivation of C. neoformans from blood or cerebrospinal fluid. The 
waiting time for results of this test is longer then in case of diagnostic of fungal 
infections with Candida due to a longer incubation time and can take even up to 7 days. 
Detection of capsule antigens Cryptococcus spp. in serum or cerebrospinal fluid. Sensitivity of 
the method increases the parallel marking of antigens in serum and PMR. 
Diagnosis of cryptococcosis can be determined only based on joined results of clinical, 
radiological and microbiological tests, (microbiology, histology, serology), each of those 
elements should be carefully considered. 
4.4 Serological diagnostic  
The current use of serological diagnostic is based on the detection of specific fungi species – 
mannoproteins, which have the role pf antigen markers. In the period of sustained systemic 
fungal infection, those antigens occur in the blood stream temporarily, are easily eliminated 
by the formed immunological complexes and by way of endocytosis through the Kupffer 
cells in the liver. Regular monitoring of their presence in systemic fluids has a great practical 
value in high risk patients. 
In diagnostics of invasive aspergilosis (IA) detection of the galactomannan (GM) antigen in 
the blood stream is valuable (GM). GM is a polysaccharide of the vascular wall of mould 
fungi belonging to the Aspergillus species (A. fumigatus, A. flavus, A. niger, A.terreus and 
other).  
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A positive test result for Aspergillus is one of the microbiological criteria recommended by 
the European Organization for Research and Treatment of Cancer and the Mycosis Study Group 
(EORTC/MSG) to determine IA, despite negative results in classic mycological tests in 
patients with haematological neoplasm.  
Using of similar criteria seams to be justified for diagnosis of IA in vascularised organ 
recipients, including kidneys. For the purpose of maximising test sensitivity it should be 
performed at least once a week for patients in the high risk group.  
For al patients with a positive result it is recommended to repeat the test with anew blood 
sample.  
According to the EORTC/MSG criteria two consecutive positive results are necessary to 
classify the test as a real positive. 
GM detection sensitivity depends on the infection localisation. In the localised invasive 
pulmonary aspergilosis the sensitivity of the method is significantly lower compared to the 
disseminated form. Monitoring of GM levels can be useful in infection course prognosis – a 
drop of the levels can be connected to good prognosis.  
IC serodiagnostic (invasive candidosis) is based on the detection of mannan antigen 
circulating in serum, which is the main component of the cellular wall of a Candida species 
fungi. Mannan is a highly immunogenic polysaccharide antigen with immunomodular  
characteristics. It allows to use in IC diagnostics parallel monitoring of circulating mannan 
and titre of antimannan antibodies.  
Parallel detection of both markers allowed to increase the sensitivity to 80% and to 93% the 
specificity of the method. Detection of circulating Candida spp. antigen in serum or plasma 
should enhance IC diagnostic in high risk patients regarding to sensitivity and detection 
time of infection development. Among Candida antigens, mannan which is the main 
component oft he cellular wall of yeast-like fungi from Candida species, appears to be one of 
the most important biomarkers in the diagnostic of invasive candidosis.  
Regular testing of IC high risk patients, connecting the detection of mannan antigen is 
helpful in diagnostic of invasive candidosis.  
The usefulness of testing levels of antibodies in patients treated with immunosuppressants 
is controversial, but in the period of graft stability in patients without additional problems 
can be helpful, as long as parallel marking of mannan antigen is performed.  
It should be kept in mind that the highest sensitivity is proved in IC diagnostic for 
C.albicans, C.glabrata, C.tropicalis etiology. The lowest sensitivity of mannan detection and 
mannan antibodies, 40-50% applies for infections with C.krusei, C.parapsilosis, C.quilliermondii 
etiology. 
Beta-glucan detection methods in serum (Fungitell-Associates of Cape Cod) proposed as 
marker in IC diagnostic has many gaps, a positive result does not allow to determine a 
fungal etiological factor, allows only to differentiate between a fungal and bacterial 
infection. Additionally the test has a low specificity and a high cost of marking and 
expensive equipment means that it is rarely used in routine diagnostic. 
4.5 Molecular biology methods 
Development of molecular techniques, which took place in past years allowed to introduce 
routine microbiological diagnostic to the tests based on detection of nucleic acids of 
microorganisms.  
In mycological diagnostic genetic methods are used for microorganism detection in material 
sampled from patients, as well as identification of specific species in this material. It has to 
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be underlines that they should be used as complimentary to the classic tests protocol or as a 
confirmation of its results.  
Molecular methods should not be used instead of classic diagnostic techniques.  
Their application with great success serve in diagnostic of infections difficult to detect with 
conventional cultivation methods.  
Most tests are restricted to detecting of frequently occurring and consequently the most 
important clinically species, which are factors in general infection such as Aspergillus 
fumigatus or Candida albicans.  
Although lately molecular identification tests are introduced for a wider group of fungal 
pathogens.  
They have been developed for detection of some of the species Aspergillus: A. flavus, A. niger, 
A. versicolor, A. terreus and A. nidulans as well as etiological factors for zygomycosis isolated 
from clinical materials sampled from patients with a general infection.  
In case of detection of ethological infections with yeast-like fungi, the newest application of 
molecular tests are for pathogens from the non-albicans group Candida spp.: C. glabrata, C. 
tropicalis, C. parapsilosis, C. krusei, species with an undeniable clinical expansion in recent years. 
Detection methods in use are usually based on techniques which are modifications of the 
standard reaction PCR: real- time PCR, nested PCR, multiplex PCR to detect the ribosome 
gens RNA: 18s rRNA, 28s rRNA or regions ITS1 and ITS2.  
Real-time reaction PCR is characterised by a fast analysis and does not require an 
electrophoretic test of products.  
The reaction is based on the standard PCR method, allows a fast identification and 
quantitative assessment of the pathogen in a clinical sample. Nested PCR is a modified 
standard reaction in which two pairs of starters are being used: outer and inner , with 
different melting temperatures. The product received with outer starters becomes a live 
matrix for reaction with inner starters. The product received in the first stage – DNA 
fragment with a sequence specific for microorganisms in the second reaction stage is 
classified to the searched for species. 
Multiplex PCR method differs from the classic method only slightly.  
The reaction is performed in the same way, but with a use of more then one pair of starters 
with a similar melting temperature, which allows to detect more then one pathogen present 
in the clinical sample.  
The choice of material for genetic testing is based on the localization of the infection.  
In case of general infections, it is recommended to perform full blood tests on the patient, 
from which the DNA will be extracted in search of the pathogen.  
Currently more often, particularly in mycosis diagnostics, applications are being used which 
do not allow for diagnostic in Rother clinical material:  
- tissue biopsy,  
- cerebrospinal fluid and Rother systemic fluids,  
- bronchial washings (BAL),  
- expectoration,  
- tracheal aspiration.  
Methods based on molecular techniques are characterised by higher sensitivity and 
specificity then classic cultivation. 
 It is estimated that real-time PCR sensitivity for Candida has 81-100% sensitivity and 
specificity from 97 to 86%.  
While using the nested PCR method for Candida the reaction sensitivity can achieve 86-79%, 
and specificity 54%. Sensitivity in multiplex PCR is 98% with specificity of 88%.  
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Specificity and sensitivity in real-time PCR for Aspergillus fumigatus oscillates around 100% 
and depends on the amount of material sampled for testing.  
Despite a sorter time needed for the performance of diagnostics, and in result of the waiting 
time for results, molecular methods hale some restrictions.  
The first is the cost of testing, surely higher then in case of classic methods.  
Another is a lack of possibility to determine sensitivity spectrum for antimycotics.  
It is necessary to perform his test with the classic method.  
It should be stressed that the possibilities of use for molecular testing is restricted to 
detection and identification of pathogens most frequently occurring in clinical material with 
the exception of the rare ones, which often cause serious infections.  
5. Diagnostics algorithm for general fungal infection risk  
5.1 Diagnostics algorithm for general fungal infection risk minimization in patients 
after kidney allotransplantation  
In result of many years of observation of a 1301 kidney recipients from cadavers and/or a 
related donor (including 213 with diagnosed diabetes) a scheme of diagnostic procedure 
Has been developed, for timely diagnostic of fungal infection, differentiation from 
colonization with opportunistic fungi strains.  
Influence of the fungal infections on an early and late function of the transplant has been 
analyzed and an algorithm has been developed for diagnostic procedure minimizing the 
risk general fungal infections in patients after a kidney allotransplantation.  
For most patients a 3-drug immunosuppressive protocol has been used: Cyclosporine A 
(CsA) or tacrolimus (FK) with glucocorticosteroids (GS), with antiproliferative preparations: 
mycophenolate mofetil (MMF) or azathioprine (AZA), some of the patients received an 
immunosuppression induction with biological agents (ATG, OKT3). 
5.2 An algorithm for an effective diagnostic procedure minimizing the risk of general 
fungal infections in kidney recipients  
An algorithm for an effective diagnostic procedure minimizing the risk of general fungal 
infections in kidney recipients should include: 
- strategy for a quick diagnostic of systemic mycosis in case of justified suspicion of such 
infection 
- tactic of routine diagnostic minimizing the risk of developing a fungal infection in the 
general population of kidney recipients 
- strict criteria for choosing of recipients from the high risk group for fungal  
- programs for active monitoring of recipients from the high risk group. 
5.3 Strategy for a quick diagnostic of systemic mycosis in case of justified suspicion 
The diagnostic procedure should be based on all available testing methods: clinical, 
radiological, histological, classic microbiology diagnostic, serological methods, and 
molecular biology. It should be underlined that every diagnostic method has serious 
restrictions, the decision about the necessary implementation of a antifungal therapy should 
be based on the interpretation of a number of tests. The basic and crucial element of each of 
the schemes outlined above remains cultivation of etiological factor IFI from materials 
sampled from the patient: blood and other systemic fluids, biopsy materials, materials from 
lower airways, urine, smears from the oral cavity, throat, rectum and other parts, faeces and 
other materials sampled from the patient, regarding to the clinical situation at hand.  
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Microbiological criteria for diagnosis of general mycosis are: 
- positive results for blood cultures and other physiologically sterile body cavities 
- determination of fungi presence in the direct preparation from the tested material 
- identification of antigens circulating by serological methods 
- identification of genetic fungal material in clinical samples from usually sterile parts 
- identification of specific antibodies  
- determination of specific fungal enzymes in urine or other systemic fluids 
- determination of morphological elements of the fungi in tissues sampled by biopsy. 
Differentiation of colonization from infection: 
- simultaneous cultivation of strains of the same species from different sampling 
locations (at least three) 
- multiple cultivation of strains of the same species from one sampling location 
- simultaneous occurrence of fungal antigens in serum or other naturally sterile systemic 
fluids  
- significant (at least 4 times) of the antibodies titre in serum 
- occurrence of hydrolytic enzymes specific for a species in systemic fluids.  
The proposal of a procedure in cases of suspected invasive fungal infections scheme is 
presented in figure 3. 
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Fig. 3. Diagnostic algorithm for prevention of invasive fungal infection in solid organ 
transplant recipients. 
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5.4 Routine diagnostic tactic for minimizing risk of fungal infection in kidney 
recipients without risk factors disorders  
Kidney recipients without additional risk factors should be monitored for a surviving skin, 
mucosa, urinogenital tract colonization with a classic microbiological method. Proposed is a 
regular cultivations for fungi in urine, oral cavity smears and qualitative diagnosis of yeast-
like fungi present in the gastrointestinal tract.  
Frequency of cultivations depends on the period after the Tx. In an early period it is justified 
to sample materials for microbiological testing not less then once every 5-7 days. In the 
second period once every 2-3 weeks. In the third – once every 1-2 months. 
5.5 Strategy of diagnostics-prophylactic procedure minimizing the risk of a systemic 
fungal infection in kidney recipients with a specific predisposition  
A more aggressive scheme should be applied in cases of additional risk factors for a general 
fungal infection.  
In the early period after Tx, presence factors determined before Tx are very important:  
- skin and mucosa colonization by yeast-like or mould fungi  
- immunosuppression induction with biological agents in highly immunized patients  
- therapy with broad-spectrum antibacterial agents 
- blood transfusions 
- a particularly important risk is a possibility of colonizing factor or causing a fungal 
infection in donor transmission from donor-recipient, especially in a diseased donor . 
To exclude such risk factors it is necessary to perform blood and urine cultivation for 
fungi  
- contamination of preservative fluids with fungi  
- risk factors occurring in the early period after Tx: 
- skin and mucosa colonization with strains of yeast-like fungi 
- bacterial infections 
- another kidney transplantation 
- acute insufficiency of the transplanted kidney 
- repeated surgery due to early postoperative complications 
- prolonged transplantation time  
- treatment of acute transplant rejection with high doses of steroids or biological agents 
- elevated levels of the basic immunosuppressive scheme 
Risk factors in the second period after Tx: 
- skin or mucosa colonization with yeast-like fungi strains 
- treatment of acute transplant rejection with high doses of steroids or biological agents 
- infection or reactivation of infections with immunomodulatory viruses: CMV, HHV, 
EBV 
- leukopenia, hypogammaglobulinemia 
- repeated bacterial infection 
- long-term antibiotics therapy 
Risk factors in the third period after Tx:  
- skin or mucosa colonization with yeast-like fungi strains 
- treatment of acute transplant rejection with high doses of steroids or biological agents 
- infection or reactivation of infections with immunomodulatory viruses: CMV, HHV, 
EBV 
www.intechopen.com
 Handling of Fungal Infections in Patients with Chronic Immunosuppression Post Renal Transplant 
 
61 
- leukopenia, hypogammaglobulinemia 
- repeated bacterial infection 
- long-term antibiotics therapy 
- chronic nephropathy of the transplanted kidney 
- treatment of neoplastic diseases. 
With the co-occurrence of two or more risk factors it a broader routine procedure, based on 
classic mycological diagnostic methods needs to be considered.  
Together with performing cultivation of clinical samples for fungi on a regular basis, we 
recommend regular, weekly mannan, galactomannan and  glucuronoxylomannan antigen 
marking, in serum with immunoenzyme method.  
5.6 Therapeutic-prophylactic procedure - conclusions  
Implementation of a therapeutic procedure, as far as it is possible, should each time be 
procedure by the identification of the etiological factor of the fungi infection species, taking 
into account natural resistance or a naturally lowered sensitivity to antimycotic substances.  
In 7744 microbiological test of material sampled from kidney recipients, positive cultivation 
for fungi were received in 475 samples (6.13%). Fungi strains causing infections in his group 
of recipients belong mostly to the non-albicans Candida spp., in which a large group are 
strains with a diversified sensitivity to antimycotics. Candida albicans was isolated only in 
38.1%, where recently we domination of his species in vascularized organs recipients has 
been observed.  
The participation of species which have replaced C. albicans is concerning, selected by an 
irrational treatment of prophylactic. Those are the strains with a restricted sensitivity to the 
available antimycotics, mostly from the azole group, resistant to flukonazole, namely:  C. 
glabrata, C. krusei, C. kefyr, C. inconspicua, Trichosporon asahi. It has been proven that species 
with a natural resistance or natural sensitivity to flukonazole – C. glabrata and C.krusei make 
up for 40%.  The acquired resistance to flukonazole has been observed in 5.27% of strains. 
Clinical material from which the fungi hale been cultivated, were sampled mostly from the 
urinary and respiratory tract, then from drainage and postoperative wounds and blood. 
Fungemia were caused only by strains belonging to the non-albicans Candida spp.  
From literature and our own data appears that the popular use of flukonazole in antifungal 
prophylactic caused  a negative selection of resistant strains. In this period it has also an 
increased rate of deaths due to general fungal infections with the genus  Aspergillus has been 
observed. 
Antifungal infection prophylactic can not be used commonly, but only in clinically justified 
cases, and prophylactic should be even given up, on behalf of active monitoring of 
recipients and progressive therapy. In this cases an implementation of drugs other then 
flukonazole or amphotericin B, Itrakonazole, Posaconazole should be considered. In 
prophylactic the toxicity of the preparations and resulting growing resistance should be 
considered. 
Empirical therapy. In cases of suspected invasive fungal infection based on clinical evidence 
the appropriate drug would be amphotericin B or its liposomal forms and Itraconazole and 
new azoles – Voriconazole, Posaconazole as well as caspofungin. Flukonazole can be used 
only in large doses only in wards, where natural species resistant to flukonazole occur rarely 
and no prophylactic product has been used. 
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Treatment of diagnosed mycosis. In confirmed cases of systemic mycosis, the drug used 
should take into account the sensitivity to the drug of the isolated strain with a marked MIC 
(minimal inhibitory concentration). The dose should be calculated for each patient 
individually based on the MIC value. In severe cases it is possible to use a joined treatment. 
The length of the treatment depends on the clinical state of the patient, it usually takes a few 
weeks. Postoperative complications requiring a new operation bear a high risk of a fungal 
infection.  
Due to this it appears justified to begin antimycotic treatment from the start of a repeated 
surgery and to perform an earlier decontamination of the gastrointestinal tract from fungal 
flora.  
Relatively new group of antimycotic drugs are echinocandins. To this group belong: 
caspofungin, anidulafungin, micafungin. The mechanism of echinocandins is based on the 
inhibition of the polysaccharide glucan synthesis (1-3β-D-glucan), which is one of the main 
components of the fungi cellular wall.  
Diminishing the concentration of the glucan in the cellular wall leads to changes in the 
permeability of the membrane and its osmotic instability, which eventually leads to cell 
lysis. Echinocandins can be only administered intravenously due to very low bioavailability 
in oral administration.  
In adult patients the pharmacodynamic of those drugs is similar – all of them are used 
intravenously in one daily dose. They are eliminated from the organism by way of a non-
enzymatic decomposition All echinocandins do not require dose modifications in case of 
renal insufficiency and renal replacement therapy.  
Caspofungin and micafungin are metabolized in a small way in the liver, but without the 
cytochrome P450 superfamily enzymes. Caspofungin is the only echinocandins which 
requires a diminished dose in cases of moderate or severe liver insufficiency.  
Echinocandins due to their mechanism are effective for fungi of the Candida and Aspergillus 
species similar to classic and lipid forms of amphotericin B. In a multiple site, randomised 
double blind a similar efficacy of caspofungin therapy with liposomal amphotericin B in 
treatment of fungal infection of the oesophagus in adults has been confirmed. Caspofungin 
has been better tolerated by the patients.  
According to the IDSA 2009 guideline echinocandins are recommended as first choice drugs 
in fungemia treatment, particularly caused by C. glabrata strains in patients with 
neutropenia and previously treated with antimycotics from the azoles group. In the 
population of patients without neutropenia echinocandins are recommended as alternative 
therapy. Particularly justified is the use of echinocandins in case of fungemia due to their 
unique ability to penetrate the biofilm environment and to inhibit outer-cellular matrix 
composition production. This characteristics of echinocandins can have great significance in 
the inhibition of pathomechanisms in fungemia  
Echinocandins also find use in therapy of infections with mould fungi treatment, mostly 
those belonging to the Aspergillus species, though it is restricted due to fungistatic effect of 
echinocandins on this type of microorganisms.  
Caspofungin is recommended in treatment of invasive cadidosis and invasive aspergillosis 
in patients who hale previously not responded to therapy or intolerant to other antifungal 
drugs.  
Anidulafungin approved by the FDA for treatment of esophagus candidosis, candidemia 
and other complications of infections with Candida spp. It Has been proved in clinical studies 
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that  anidulafungin has higher efficacy compared to flukonazole in patients with invasive 
candidosis and fungemia.  
Micafungin is recommended in treatment of invasive cadidosis, for treatment of esophagus 
candidosis, prophylactic of infections caused by Candida spp. in patients  with allogenic 
blood stem cells transplants. An important advantage of micafungin is its small potential for 
drug interactions. This applies for immunosuppressants: cyclosporine A, tacrolimus, 
mycophenolate mofetil. With a simultaneous treatment with sirolimus, Itraconazole or 
nifedipine with micafungin the patent should be monitored for toxic effects and if necessary 
the dose should be decreased. Lately reports of clinical efficacy of micafungin in treatment 
of infections caused by appear more frequently non-albicans Candida species and Aspergillus 
spp. In patients with immunological insufficiency or without.  
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